Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

3. Alzheimer's Disease Treatments: With the recent approval of donanemab, Eli Lilly is well-positioned in the Alzheimer's disease space, a market with significant unmet needs and growth potential.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly and Company LLY will report its fourth ... Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have been much higher than the third-quarter number of $1.4 million.